1. Home
  2. SDA vs DMAC Comparison

SDA vs DMAC Comparison

Compare SDA & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SDA
  • DMAC
  • Stock Information
  • Founded
  • SDA 2007
  • DMAC 2000
  • Country
  • SDA China
  • DMAC United States
  • Employees
  • SDA N/A
  • DMAC N/A
  • Industry
  • SDA Blank Checks
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • SDA Finance
  • DMAC Health Care
  • Exchange
  • SDA Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • SDA 265.8M
  • DMAC 310.1M
  • IPO Year
  • SDA N/A
  • DMAC N/A
  • Fundamental
  • Price
  • SDA $2.34
  • DMAC $6.96
  • Analyst Decision
  • SDA Buy
  • DMAC Strong Buy
  • Analyst Count
  • SDA 1
  • DMAC 3
  • Target Price
  • SDA $3.50
  • DMAC $12.33
  • AVG Volume (30 Days)
  • SDA 64.9K
  • DMAC 343.5K
  • Earning Date
  • SDA 09-12-2025
  • DMAC 11-12-2025
  • Dividend Yield
  • SDA N/A
  • DMAC N/A
  • EPS Growth
  • SDA N/A
  • DMAC N/A
  • EPS
  • SDA N/A
  • DMAC N/A
  • Revenue
  • SDA $458,905,000.00
  • DMAC N/A
  • Revenue This Year
  • SDA $20.77
  • DMAC N/A
  • Revenue Next Year
  • SDA $19.32
  • DMAC N/A
  • P/E Ratio
  • SDA N/A
  • DMAC N/A
  • Revenue Growth
  • SDA 24.15
  • DMAC N/A
  • 52 Week Low
  • SDA $2.12
  • DMAC $3.19
  • 52 Week High
  • SDA $11.28
  • DMAC $7.49
  • Technical
  • Relative Strength Index (RSI)
  • SDA N/A
  • DMAC 58.60
  • Support Level
  • SDA N/A
  • DMAC $6.75
  • Resistance Level
  • SDA N/A
  • DMAC $7.13
  • Average True Range (ATR)
  • SDA 0.00
  • DMAC 0.28
  • MACD
  • SDA 0.00
  • DMAC -0.06
  • Stochastic Oscillator
  • SDA 0.00
  • DMAC 50.00

About SDA SunCar Technology Group Inc.

SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: